Next Article in Journal
Immunotherapies in Non-Hodgkin’s Lymphoma
Next Article in Special Issue
Reply to Auclin et al. Comment on “Hopkins et al. Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial. Cancers 2021, 13, 1176”
Previous Article in Journal
Stereotactic Body Radiotherapy for Patients with Lung Oligometastatic Disease: A Five-Year Systematic Review
Previous Article in Special Issue
Proteomic Profiling of Tissue Exosomes Indicates Continuous Release of Malignant Exosomes in Urinary Bladder Cancer Patients, Even with Pathologically Undetectable Tumour
 
 
Comment

Article Versions Notes

Cancers 2021, 13(14), 3624; https://doi.org/10.3390/cancers13143624
Action Date Notes Link
article xml file uploaded 20 July 2021 09:33 CEST Original file -
article xml uploaded. 20 July 2021 09:33 CEST Update https://www.mdpi.com/2072-6694/13/14/3624/xml
article pdf uploaded. 20 July 2021 09:33 CEST Version of Record https://www.mdpi.com/2072-6694/13/14/3624/pdf
article html file updated 20 July 2021 09:34 CEST Original file https://www.mdpi.com/2072-6694/13/14/3624/html
Back to TopTop